
Dexrazoxane, a cardioprotective drug was found to prevent long-term heart damage in children receiving chemotherapy, reveals review published in the British Journal of Clinicial Pharmacology .
Advances in cancer therapy have significantly increased survival rates in children with cancer, but these survivors face increased long-term risks of experiencing side effects related to their treatment. For example, anthracyclines, which are among the most commonly used chemotherapeutic agents for treating children with cancer, are extremely effective, but they are also increase the risk of damage o the heart.
When Steven Lipshultz, MD, of Wayne State University School of Medicine and the Children's Hospital of Michigan, in Detroit, and his colleagues reviewed the medical literature, they found that anthracyclines can increase patients' risks of developing cardiomyopathy, heart failure, heart attacks, valve disease, pericardial disease, hypertension, and other cardiovascular-related conditions. The team also found that dexrazoxane has proven helpful in preventing many of the cardiotoxic effects of anthracycline treatment, without reducing its anticancer effects.
The authors stressed that dexrazoxane should be considered as a part of therapy for young patients treated with anthracyclines. "If implemented, more children with cancer who are treated with anthracyclines may be cured of their malignancy and with less chemotherapy-associated toxicity and late effects," said Dr. Lipshultz.
Source: Eurekalert
Advertisement
|